Therapy News and Research

RSS

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

People hospitalized with certain rare blood cell disorders frequently receive a treatment that is associated with a two- to fivefold increase in death, according to a new study that reviewed hospital records nationwide. The study authors recommend that for these rare disorders, doctors should administer the treatment, a platelet transfusion, only in exceptional circumstances.

14 Jan 2015

Urinary levels of novel biomarkers linked to adverse long-term outcomes in AKI patients

High levels of two novel urinary biomarkers early in critical illness are associated with adverse long-term outcomes in patients with acute kidney injury (AKI), according to an international, multi-center study led by University of Pittsburgh School of Medicine Researchers.

14 Jan 2015

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody ("mAb") targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

14 Jan 2015

Reducing fears key to success of CBT or GET in people with chronic fatigue syndrome

Reducing fears that exercise or activity will make symptoms worse is one of the most important factors determining the success of cognitive behaviour therapy (CBT) or graded exercise therapy (GET) in reducing fatigue and improving physical function in people with chronic fatigue syndrome (CFS), according to new analysis of data from the PACE trial, reported in The Lancet Psychiatry journal.

14 Jan 2015

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.

14 Jan 2015

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Sophia Genetics, the European leader in Data Driven Medicine, has today obtained CE-IVD marking for its solution to detect BRCA1/2 associated genetic variants in live tumours.

14 Jan 2015

Study: Race and ethnicity may affect breast cancer diagnoses, survival

Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biological differences, according to a study in the January 13 issue of JAMA.

14 Jan 2015

Research findings may lead to new treatment for hypothyroidism

An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.

14 Jan 2015

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.

14 Jan 2015

Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

UCLA transplantation researchers have developed a novel method that more accurately calculates the risk of disease recurrence in liver cancer patients who have undergone a liver transplant, providing a new tool to help physicians make treatment and surveillance decisions.

14 Jan 2015

Cold atmospheric pressure plasma treatment may reduce risk of transmitting norovirus

Treating surfaces with cold atmospheric pressure plasma (CAPP) may reduce the risk of transmitting norovirus, a contagious virus leading to stomach pain, nausea and diarrhea, according to a new study.

14 Jan 2015

Scientists find that blocking hormone reduces stress-induced infertility in female rats

University of California, Berkeley, scientists have discovered that chronic stress activates a hormone that reduces fertility long after the stress has ended, and that blocking this hormone returns female reproductive behavior to normal.

13 Jan 2015

Digital healthcare communications: an interview with David Hunt, CEO of HAVAS LYNX Europe

Digital has excited the industry, it has hinted at a brighter future, a potential competitive advantage and most importantly a better purpose, however like many others, it has not been the revolution it might have been.

13 Jan 2015

How quickly smokers metabolise nicotine may point to best quitting method

The success of different smoking cessation treatments could be predicted by how quickly smokers break down (metabolise) nicotine in their bodies, according to new research published in The Lancet Respiratory Medicine journal.

13 Jan 2015

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114, a selective tyrosine kinase inhibitor, is active against native and mutated forms of the BCR–ABL oncogene in Philadelphia chromosome-positive leukaemias, according to preclinical cellular and in vivo results published in Leukemia.

12 Jan 2015

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows.

12 Jan 2015

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs.

12 Jan 2015

Study demonstrates that pelvic floor muscle training improves erectile function

Preliminary results of a four-month clinical trial offer hope for the thousands of baby boomer men turning 50 every minute, with nearly 6-in-10 of them experiencing erectile dysfunction. Proving pelvic floor exercise can help turn back the clock on sexual decline, the study demonstrates that weighted resistance training improves erectile function in both healthy men and those with erectile dysfunction.

12 Jan 2015

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, and Human Longevity, Inc., the human health information technology and health care company, today announced that HLI will have access to PGDx's cancer genomics solutions to expand its analysis of cancer genomes, including CancerSelect, PlasmaSelect, CancerXome, METDetect and CancerComplete.

12 Jan 2015

Tandem Diabetes Care receives FDA clearance to market t:flex Insulin Pump

Tandem Diabetes Care, Inc., a medical device company and manufacturer of the t:slim Insulin Pump, today announced that the U.S. Food and Drug Administration has granted the Company clearance to market the t:flex Insulin Pump. At 480 units, the insulin reservoir of the t:flex Pump has the largest capacity currently available in the United States.

12 Jan 2015

Therapy News and Research

Platelet transfusion treatment increases death in people with certain rare blood cell disorders

Urinary levels of novel biomarkers linked to adverse long-term outcomes in AKI patients

3SBio, PharmAbcine sign licensing agreement to develop and market DIG-KT

Reducing fears key to success of CBT or GET in people with chronic fatigue syndrome

PharmaMar to begin PM1183 Phase III trial in combination with doxorubicin in SCLC

Sophia Genetics obtains CE-IVD marking for BRCA1/2 testing solution

Study: Race and ethnicity may affect breast cancer diagnoses, survival

Research findings may lead to new treatment for hypothyroidism

Intrexon and ZIOPHARM Oncology sign exclusive licensing agreement with MD Anderson

Researchers develop novel method to predict risk of liver cancer recurrence after transplantation

Cold atmospheric pressure plasma treatment may reduce risk of transmitting norovirus

Scientists find that blocking hormone reduces stress-induced infertility in female rats

Digital healthcare communications: an interview with David Hunt, CEO of HAVAS LYNX Europe

How quickly smokers metabolise nicotine may point to best quitting method

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Study demonstrates that pelvic floor muscle training improves erectile function

HLI gains access to PGDx's cancer genomics solutions to expand cancer genome analysis

Tandem Diabetes Care receives FDA clearance to market t:flex Insulin Pump

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News